President Donald Trump’s executive order imposing a 10% tariff on Chinese imports is likely to drive up the cost of generic drugs in the United States and exacerbate drug shortages, experts say.
Jiang Su Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China Department of Medicinal Chemistry, School ...
China Resources Pharmaceutical Group (CR Pharmaceutical ... drug after findings from a preclinical research project at the University of Hong Kong showed a close association between Alzheimer ...
Jiangsu Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China Jiangsu Key Laboratory of Drug Design and ...
including the aviation composite materials R&D and manufacturing base of the China National Building Material Group Co Ltd, Qilu Pharmaceutical's global R&D headquarters for drug innovation ...
Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the chairman of Xtalpi wants to help ...
We would like to thank professor Wenxi Tang of China Pharmaceutical University for her guidance on the direction of the application of system dynamics in health policy. We would like to thank China’s ...
As the current largest group purchasing organization in the world, certainly, the NCDP initiative in China has generally successfully established a “buyer-cartels” to countervail pharmaceutical ...
2 State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China 3 Department of Integration of Chinese and Western Medicine, School of ...
China's healthcare regulator on Sunday defended the efficacy of off-patent medicines it had approved to be distributed ...
President Trump’s tariffs in China are in place and hitting all products imported from the country — including a number of pharmaceutical drugs that Americans rely upon. Chinese imports ...
China's State Council issued new Anti-Monopoly Guidelines for the Pharmaceutical Sector (the "Guidelines") effective January 24, 2025. The ...